These results were further strengthened by the RT-PCR data that validated the increased expression of TALNEC2 in GBM compared to low-grade tumors and normal brain specimens and in GBM derived from patients of short-term survival (9 months) as compared to patients with long-term survival (>36 months). The gene discussed is LINC01116; the disease is glioblastoma.